![Sample our Physical Sciences journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/110819/TOC-Subject-Sample-2021-Physical-Sciences.jpg"})
Abstract
Arotinolol and its main metabolite, AC 623, both antihypertensive agents with β blocking properties were simultaneously determined in human plasma and urine, using solid-liquid extraction and reversed phase HPLC with fluorimetric detection; U. V. detection could be added as a further control of the specificity of the method.
Extraction yields were satisfactory and stable. Calibration curves in plasma of 0 to 100 ng/ml Arotinolol and 0 to 10 ng/ml AC 623 were used; in urine concentrations of 0 to 1000 ng/ml of both drugs were quantified. Concentrations of 2 ng/ml Arotinolol and 1 ng/ml AC 623 in plasma and of 20 ng/ml of both drugs in urine could be quantified with good accuracy.
Repeatability (intra-day; n = 6) was studied at 3 concentrations covering the standard curve ranges. Reproducibility was estimated from calibration curves (10 in plasma and in urine) carried out during a pharmacokinetic study in man. Specificity was verified in general and with regards to another metabolite present in man.
The method is shown to be well adapted for accurate determination of Arotinolol and its main metabolite in biological samples during pharmacokinetic and clinical studies.